Colleagues,

Please find below the National Notifiable Diseases Surveillance System (NNDSS) Modernization Initiative (NMI) Technical Assistance (TA) Coordination Team Update for October 9, 2015. These e-mail updates are a collaboration among the Centers for Disease Control and Prevention (CDC), Council of State and Territorial Epidemiologists (CSTE), and the Association of Public Health Laboratories (APHL) and are sent biweekly in an effort to keep reporting jurisdictions and other partners and stakeholders updated on the progress of NMI.

For more information on NMI, please see the NMI FAQS at http://www.cdc.gov/nmi/faq.html. If you have questions not answered in the FAQs, please send them to edx@cdc.gov.

NNDSS Modernization Initiative Biweekly Update
October 9, 2015

NMI Overall Updates
- For the 10/26/15 CSTE State Epidemiologist Call, CSTE has invited the NMI team to provide a project update, including highlights of NMI accomplishments and expectations for the near future. The NMI team will answer questions and gather feedback from the state epidemiologists on the call.
- CSTE has asked the NMI team to participate in the November 2015 CSTE Surveillance Summit, which will address data and surveillance system harmonization and standardization.
  - Discussions will feature the 2015 CSTE Executive Board position statement 15-EB-01, "Common Data Structure for National Notifiable Diseases"; potential collaborations within the harmonization process; and how harmonized surveillance efforts will affect and support other public health practices such as electronic case reporting.
  - More details about the event will be provided when available.

Message Mapping Guide Development Updates
- During October, the Message Mapping Guide (MMG) development team will make minor updates to the MMGs, Test Scenarios (TS), and Test Messages (TM) for Generic v2, Hepatitis, STD, Congenital Syphilis, Mumps, and Pertussis to improve consistency in format and wording across these documents.
  - The team is creating quality assurance (QA) checklists for each artifact.
  - The team expects to post updated pilot test-ready versions of all the MMGs and their associated artifacts to the Draft MMG Web Site in November.
- The team posted a frequently asked questions document about case notification implementation to the Draft MMG Web Site under "Related Documentation."
- The team posted the updated National Condition Reporting Case Notification Message Structure Specification/Profile Release 3.0 to the Draft MMG Web Site.
- The 30-day Federal Register Notice for the 2015 Office of Management and Budget (OMB) Paperwork Reduction Act package for NNDSS was posted on 9/29/15.
- **MMG Status Updates:**
  - **Arboviral MMG (Message Design and Development)**
    - The CDC program approved the proposed data elements for inclusion in the draft Arboviral MMG.

- - Requirements analysis is now complete, and the guide has moved into the Message Design and Development stage of the lifecycle.
  - **Varicella MMG (Message Design and Development)**
    - Requirements analysis is 100% complete.
    - The CDC program has reviewed both sections of the draft MMG and provided feedback.
  - **Mumps and Pertussis MMGs** (Stage I—Draft Phase)
    - The CDC program approved the pilot test-ready Mumps and Pertussis MMGs, TS, TM, and annotated case surveillance worksheets.
    - The team will post all artifacts as pilot test-ready drafts after making the QA consistency updates to the MMGs. The draft Mumps and Pertussis MMGs were removed from the Draft MMG Web Site in September.
  - **Congenital Syphilis and STD MMGs** (Stage II—Pilot Test-ready Draft Phase)
    - The team added a new data element for neurological manifestations to the STD MMG and shared a draft with the program for feedback. The team will submit a change request for this change.
    - The team will post revised versions of the pilot test-ready Congenital Syphilis and STD MMGs and artifacts to the Draft MMG Web after making the QA consistency updates.
  - **Generic v2 and Hepatitis MMGs** (Stage II—Pilot Test-ready Draft Phase)
    - The MMG development team updated the pilot test-ready versions of the Generic v2 and Hepatitis MMGs and their artifacts to incorporate new LOINC codes.
    - The team revised TM #3 for the Generic v2 MMG because it contained the event code for Listeriosis, which is not a condition that can be submitted by using the Generic v2 only MMG. Generic TM #3 will be updated to replace Listeriosis with foodborne botulism.
    - The team updated the Hepatitis TS with additional data for the lab and vaccine templates.
    - The team will post the revised MMGs and artifacts to the Draft MMG Web Site after making the QA consistency updates.
  - No guides are in Stage III—Final MMG Phase at this time.

Message Validation, Processing, and Provisioning System Updates

- The Message Validation, Processing, and Provisioning System (MVPS) team completed the transition of MVPS developers on 9/23/15.
  - Through October, the new MVPS developer will familiarize themselves with the MVPS code and provide CDC with an assessment of the code base prior to committing to schedules for necessary updates to the code or delivery of new code.
  - The MVPS requirements team will set up a meeting with the MVPS developer and the vendor performing the MVPS analysis of alternatives to review the MVPS requirements documentation to date.
- The team is preparing test data to test the 9/9/15 MVPS build, including message processing and data provisioning.
  - After configuring the development environment, the MVPS team loaded the 9/9/15 MVPS build for technical acceptance testing.

- o The team continues to resolve issues with the application needed for Generic v2 and Hepatitis data provisioning deployment. They have resolved permissions and data type mismatch issues and are completing the steps required for full installation of data provisioning functionality in the development environment.
  - o Generic v2 messages have been created and tested through the Message Evaluation and Testing Service (METS), and Hepatitis messages are being updated.
  - o The team is preparing detailed test cases for end-to-end testing.
- The team tested METS code from the 9/9/15 delivery and moved it into production on 9/17/15.
- The MVPS team has begun working on priority activities for METS, including reviewing the desired METS user experience, required functionality, and errors and warnings.
- The MVPS team resolved the issues between MVPS and the CDC Secure Access Management Services (SAMS) forwarder so jurisdiction user acceptance testing (UAT) is anticipated to begin soon.
- Following completion of UAT for the MVPS Dashboard and message processing functionality on 9/15/15, the MPVS test team submitted change requests to address identified defects and initiated a number of enhancement requests based on suggestions they received.
- The Data Operations and MVPS teams are working to implement changes needed to support the processes that will supply NNDSS data to the *Morbidity and Mortality Weekly Report* when data begin to flow through MVPS.
- Documentation of the data provisioning requirements for the Congenital Syphilis, Mumps, Pertussis, Arboviral, and Varicella MMGs continues.

Technical Assistance Updates

- **Update on Jurisdiction Implementation:** The National Electronic Disease Surveillance System Base System (NBS) team provides technical assistance for NBS pilot jurisdictions, and the APHL TA team provides technical assistance for non-NBS pilot jurisdictions.
  - o **Alabama:**
    - Alabama implemented the patch release for Beta 2 of the NBS 4.6 release.
    - Currently, the state is testing STD messages by using METS and migrating STD data.
  - o **Arkansas:**
    - Arkansas implemented the patch release for Beta 2 of the NBS 4.6 release.
    - All of the state's Hepatitis test scenario notifications passed METS without errors after updating the test messages to account for METS known issues.
    - The state has completed message testing in METS and is ready to conduct end-to-end testing with CDC when MVPS is ready.
  - o **California**:
    - California has produced a draft data extract for Hepatitis and STD and is currently creating the data extract for Generic v2.
    - The APHL TA team is customizing the Rhapsody route for California that will create HL7 messages based on their data extract.
  - o **Florida**:
    - Florida has completed the gap analysis for Hepatitis, STD, and Generic v2.
    - Initial HL7 test messages for Hepatitis have been created. STD test messages are currently in development. The APHL TA team will review and provide feedback on test messages as they are created.

- o **Idaho:**
  - Idaho implemented the patch release for Beta 2 of the NBS 4.6 release.
  - The state is currently testing STD messages by using the METS tool.
- o **Kentucky:**
  - Kentucky implemented the patch release for Beta 2 of the NBS 4.6 release.
  - All of the state's Hepatitis test scenario notifications passed METS without errors after updating the test messages to account for METS known issues.
  - The state has completed message testing in METS and is ready to conduct end-to-end testing with CDC when MVPS is ready.
- o **Louisiana:**
  - Louisiana implemented the patch release for Beta 2 of the NBS 4.6 release.
  - All of the state's Hepatitis test scenario notifications passed METS without errors after updating the test messages to account for METS known issues.
  - The state has completed message testing in METS and is ready to conduct end-to-end testing with CDC when MVPS is ready.
- o **Michigan**:
  - Michigan has completed the full suite of test messages for Hepatitis, STD, and Generic v2 test messages. The APHL TA team is reviewing and providing feedback on test messages as they are created.
- o **Minnesota**:
  - Minnesota has produced a draft data extract for Hepatitis, STD, and GenV2; the TA team and the jurisdiction are working on detailing requirements for a data warehouse that will be used in the HL7 message route.
  - The APHL TA team is customizing a Rhapsody route for Minnesota to create HL7 messages per the MMGs.
- o **New York State:**
  - APHL is coordinating with New York to review their development work on Generic v2.
- o **Oregon:**
  - Oregon has created HL7 test messages for Hepatitis, Generic v2, and STD.
  - The APHL TA team continues to review and provide feedback on test messages as they are created.
- o **Tennessee:**
  - Tennessee implemented the patch release for Beta 2 of the NBS 4.6 release.
  - The state is testing the base Hepatitis page and porting the legacy data to the new template.
- o **Texas:**
  - Texas implemented the patch release for Beta 2 of the NBS 4.6 release.
  - All of the state's Hepatitis test scenario notifications passed METS without errors after updating the test messages to account for METS known issues.
  - The state has completed message testing in METS and is ready to conduct end-to-end testing with CDC when MVPS is ready.
- CSTE will work with all of the pilot jurisdictions to evaluate the NMI TA efforts.
- Reminder about MMG status:
  - o MMGs in Stages I and II are considered draft and may be revised until the time they are finalized.

- Those jurisdictions selected for pilot testing of the test-ready versions (Stage II) of the MMGs should wait until contacted by the NMI TA team before using the test-ready MMGs, before implementing surveillance information system changes, and before submitting test messages to CDC.
- All other jurisdictions should not plan to submit data to CDC or implement MMG-based updates to their surveillance information systems until the final MMGs (Stage III) have been posted.
- For more information about technical assistance:
  - Please see the NMI FAQs at http://www.cdc.gov/nmi/faq.html.
  - For pilot jurisdictions: If you have questions specific to NMI TA, please contact Laura Carlton, APHL, at laura.carlton@aphl.org.
  - For non-pilot jurisdictions: If you have questions or would like to request TA through the Epidemiology and Laboratory Capacity for Infectious Diseases (ELC) Cooperative Agreement, please email edx@cdc.gov.

For more information on NMI, please see the NMI FAQS at http://www.cdc.gov/nmi/faq.html. If you have questions not answered in the FAQs, please send them to edx@cdc.gov.